Reported Earlier, Rein Therapeutics Prices $50M Public Offering Of 50M Common Shares At $1.00 Per Share; Proceeds To Fund LTI-03 Phase 2 Trial

Benzinga Newsdesk www.benzinga.com Neutral 92.8%